Compositions and Methods for Treating Adrenocortical Carcinoma and Excess Steroid Production

TECHNOLOGY NUMBER: 7401



OVERVIEW

A novel approach to addressing the pathologic effects of adrenocortical carcinoma

- Decreases cholesterol levels, inhibits cortisol secretion, and lowers mitochondrial activity
- Concurrent administration of two or all three of these drug classes is effective

BACKGROUND

The adrenal gland produces hormones that affect development, handling stress, growth, and the regulation of kidney function. Adrenocortical carcinoma (ACC) can arise from the cortex of the adrenal gland, though it is often difficult to diagnose by either radiographic or pathologic evaluation when compared to more commonly occurring and benign adrenal adenomas. ACC causes severe issues related to excess steroid production that suppresses immune responses and disrupts multiple physiological functions. Symptoms may include weight gain, muscle weakness, insomnia, abdominal pain, and weight loss. Therefore, a great need exists for agents which can address the physiologic effects of ACC and treat the underlying cancer.

INNOVATION

Researchers at the University of Michigan describe improved control of ACC symptoms through the use of two or more of the following three classes of drugs: 1) an agent capable of inhibiting cholesterol efflux, 2) an agent capable of inhibiting cortisol secretion, and 3) an agent capable of inhibiting mitochondrial activity. The medicine which addresses increases in cholesterol levels does so by inhibiting cholesterol cell membrane transporters named ABCA1 and ABCG1. The

Technology ID

7401

Category

Therapeutics and Vaccines
Life Sciences

Inventor

Tom Kerppola Veronica Burns

Further information

Tiefei Dong tiefeid@umich.edu

View online



treatment that decreases cortisol secretion inhibits the multi drug resistant gene (MDR1) related cortisol secretion and MDR1 P-glycoprotein multiple drug transporter activity. The agent that decreases mitochondrial activity or ATP synthesis does so by inhibiting mitochondrial electric chain activity related to cholesterol accumulation. Treatment regimens may include the concurrent use of two or all three of these classes of drugs.